<DOC>
	<DOCNO>NCT02247154</DOCNO>
	<brief_summary>To determine : 1 . The safety Vigam® Liquid patient primary secondary antibody deficiency ( PAD SAD ) . 2 . The efficacy Vigam® Liquid patient primary secondary antibody deficiency . 3 . The half-life Vigam® Liquid 4 month treatment . 4 . The subclass total gammaglobulin concentration infusion Vigam® Liquid .</brief_summary>
	<brief_title>A Study Safety Efficacy Vigam® Liquid Patients With Primary Secondary Antibody Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Adults ( 1880 year ) PAD SAD With low serum IgG ( &lt; 6 g/l ) history recurrent infection Requiring eligible polyvalent intravenous immunoglobulin ( IVIG ) replacement therapy Nonreactive HBsAg alanine aminotransferase ( ALT ) level less twice upper limit normal prior entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>